GNNSF Stock Genscript Biotech (GNNSF, $2.42) was a top gainer this month, soaring +10.5%

GET DAILY SIGNALS

Get AI intraday signals

GNNSF - Genscript Biotech Corp

Loading...

Price: $2.42

Daily change: +$0.22 (+10%)

Daily volume: 18.8K

Monthly price change: +$0.23 (+10.5%)

Capitalization: $4.8B

Industry: Biotechnology

Genscript Biotech (GNNSF, $2.42) was one of the top gainers for the month, rising to $2.42 per share. A.I.dvisor analyzed 786 stocks in the Biotechnology Industry for the month ending September 15, 2025 and discovered that of them (5) exhibited an Uptrend while of them (4) exhibited a Downtrend.

GNNSF's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for GNNSF turned positive on November 07, 2025. Looking at past instances where GNNSF's MACD turned positive, the stock continued to rise in of 40 cases over the following month. The odds of a continued upward trend are .

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where GNNSF's RSI Indicator exited the oversold zone, of 24 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

GNNSF may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Momentum Indicator moved below the 0 level on October 31, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on GNNSF as a result. In of 53 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

GNNSF moved below its 50-day moving average on October 09, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for GNNSF crossed bearishly below the 50-day moving average on October 14, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

The Aroon Indicator for GNNSF entered a downward trend on November 11, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. GNNSF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GNNSF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.037) is normal, around the industry mean (24.439). P/E Ratio (0.000) is within average values for comparable stocks, (63.753). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.001). Dividend Yield (0.000) settles around the average of (0.046) among similar stocks. P/S Ratio (5.571) is also within normal values, averaging (322.723).